Advertisement
JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Originally published In Press as doi:10.1074/jbc.M700759200 on March 19, 2007

J. Biol. Chem., Vol. 282, Issue 19, 14675-14683, May 11, 2007
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Supplemental Data
Right arrow All Versions of this Article:
282/19/14675    most recent
M700759200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Connors, W. L.
Right arrow Articles by Heino, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Connors, W. L.
Right arrow Articles by Heino, J.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Two Synergistic Activation Mechanisms of {alpha}2beta1 Integrin-mediated Collagen Binding*Formula

Wendy L. Connors{ddagger}, Johanna Jokinen{ddagger}, Daniel J. White§, J. Santeri Puranen, Pasi Kankaanpää{ddagger}, Paula Upla§, Mira Tulla{ddagger}, Mark S. Johnson, and Jyrki Heino{ddagger}1

From the {ddagger}Department of Biochemistry and Food Chemistry, University of Turku, FI-20014 Turku, Finland, the §Department of Biological and Environmental Science, University of Jyväskylä, FI-40014 Jyväskylä, Finland, and Department of Biochemistry & Pharmacy, Åbo Akademi University, FI-20520 Turku, Finland

Received for publication, January 26, 2007 , and in revised form, March 16, 2007.


   ABSTRACT
TOP
 ABSTRACT
INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
Activation of protein kinase C by 12-O-tetradecanoylphorbol-13-acetate (TPA) induces ligand-independent aggregation of a cell surface collagen receptor, {alpha}2beta1 integrin. Concomitantly, TPA increases the avidity of {alpha}2beta1 for collagen and the number of conformationally activated {alpha}2beta1 integrins. The structural change was shown using a monoclonal antibody 12F1 that recognizes the "open" (active) conformation of the inserted domain in the {alpha}2 subunit ({alpha}2I). Amino acid residue Glu-336 in {alpha}2 subunit is proposed to mediate the interaction between {alpha}2I domain and beta1 subunit. Glu-336 seems to regulate a switch between open and "closed" conformations, since the mutation {alpha}2E336A inhibited the TPA-related increase in the number of 12F1 positive integrins. E336A also reduced cell adhesion to collagen. However, E336A did not prevent the TPA-related increase in adhesion to collagen or {alpha}2beta1 aggregation. Thus, {alpha}2beta1 integrin avidity is regulated by two synergistic mechanisms, first an {alpha}2E336-dependent switch to the open {alpha}2I conformation, and second an {alpha}2E336-independent mechanism temporally associated with receptor aggregation.


   INTRODUCTION
TOP
 ABSTRACT
 INTRODUCTION
EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
Integrin-type cell adhesion receptors undergo functional regulation via different conformational states (1). In an inactive integrin {alpha}/beta heterodimer, the ligand binding headpiece is bent toward the cell surface (2), while an active integrin stands tall but may still have multiple activation states. Nine {alpha} subunits out of 24 human integrin heterodimers have an inserted {alpha}I (or {alpha}A) ligand binding domain, which can exist in multiple configurations of differing affinity. The conformation of {alpha}I is regulated by a spring-like mechanism formed by a conserved glutamate residue in the {alpha}7 helix acting as an intrinsic ligand of the I-like domain of the beta subunit (betaI; Refs. 3 and 4).

Avidity, the overall strength of integrin mediated interactions between cells and extracellular ligands, is multideterminant, involving the affinity of individual receptors and variations in the spatial arrangement of the integrins. The total number of receptors participating in the interaction, or valency, is expected to be larger if integrins form clusters. The relationship between conformational regulation and cluster formation has been thoroughly studied in {alpha}Lbeta2 integrin, a leukocyte receptor for intercellular adhesion molecules (5-7). Recent studies suggest that {alpha}Lbeta2 clustering takes place only after binding a multivalent ligand and that clustering strengthens adhesion after ligand binding (8). The requirement of a ligand for receptor clustering has also been reported for {alpha}Vbeta3 (9) and {alpha}IIbbeta3 integrins (10).

Four collagen receptors, {alpha}1beta1, {alpha}2beta1, {alpha}10beta1, and {alpha}11beta1, form a subgroup of {alpha}I domain containing integrins. Integrin {alpha}2beta1 is expressed on platelets, epithelial cells, and many mesenchymal cell types (11). The {alpha}2I domain, like other integrin I domains, can exist in both an "open" and a "closed" conformation (12), as well as a less frequent, intermediate form (13). Thus, {alpha}2beta1 can also be found in more than one conformation (14), likely regulated similarly to other {alpha}I domain integrins. The unique functions of collagen receptor integrins may also be governed by the regulation of the receptor distribution and local density. For example, {alpha}2beta1 and {alpha}11beta1 participate in the formation and rearrangement of collagen fibrils (15, 16), and echovirus-1-dependent clustering leads to rapid relocation and internalization of {alpha}2beta1. In this process, {alpha}2beta1 behaves differently from other integrin family members, such as {alpha}V integrins (17).

The phorbol ester TPA2 can increase the avidity of {alpha}2beta1 binding to collagen (18). We report here that while TPA induces rapid (5-15 min) clustering of cell surface {alpha}2beta1inthe absence of ligand and increases {alpha}2beta1 avidity for collagen, it also activates the integrin via a conformational mechanism involving {alpha}2E336 and intermolecular cross-talk between the {alpha}2I and beta1I domains. Aggregation of {alpha}2beta1 is independent of E336 and temporally associated with increased avidity of adhesion. We conclude that the avidity of {alpha}2beta1 for collagen is regulated by two synergistic mechanisms.


   EXPERIMENTAL PROCEDURES
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
RESULTS
 DISCUSSION
 REFERENCES
 
Cell Culture—Chinese hamster ovary (CHO) and Saos (ATCC) cells were stably transfected with human integrin {alpha}2 (19, 20), {alpha}10 subunit (21) in pAWneo2 vector, or vector only as described. The CHO-{alpha}2/{alpha}1 cell line has been described by Ivaska et al. (22). Integrin {alpha}2 mutants Y410A, E309A, and E336A were constructed by a modified QuikChange method (Stratagene). Stable CHO-{alpha}2E309A, CHO-{alpha}2Y410A, and CHO-{alpha}2E336A cell lines were created by using FuGENE6 transfection reagent (Roche Applied Science). {alpha}2 positive cells were first selected with G418 (0.5 mg/ml; Invitrogen). Additionally, positive cells were stained with integrin {alpha}2 mAb 12F1 (BD Biosciences) and anti-mouse FITC-IgG (Dako) and isolated by flow cytometry (FACSCalibur, BD Biosciences). Cell lines GD25-{alpha}2beta1 and GD25-{alpha}2beta1mut (called also GD25-{alpha}2beta1A and GD25-{alpha}2beta1Amut; kind gifts from Professor Kristofer Rubin from Uppsala University, Sweden and Professor Deane F. Mosher, University of Wisconsin) stably expressing wild type human integrin {alpha}2 subunit and either wild type mouse beta1 or beta1 carrying Y783/795F mutations in its cytoplasmic tail have been described earlier (23-25).

Cell Spreading Assay—Costar 96-well plates were coated with collagen I (col I, 5 µg/cm2; Vitrogen) or 0.1% BSA. Cells were allowed to spread in serum-free medium with 50 µM cycloheximide (Sigma) for 2 h at 37 °C. Fixed cells were analyzed by phase-contrast microscopy as described earlier (26).

Receptor Staining—100 nM TPA (Calbiochem) was added to subconfluent cells in serum free Dulbecco's modified Eagle's medium. Released cells were fixed (4% formalin) and suspended in phosphate-buffered saline with 3% BSA and 0.6% rat IgG at time points. Cells were stained with mAb (12F1 or 16B4, Serotec) and anti-mouse Alexa-488-IgG (Molecular Probes) and assayed by flow cytometry.

Cellular Adhesion Assay—Adherent cells were first treated with 10 µM bisindolylmaleimide (BIS; Calbiochem) or {alpha}2 integrin inhibitory antibody P1H5 (Santa Cruz Biotechnology), for 15 min at 37 °C when stated. Then, col I- or BSA-coated bead suspension (Ø 9.6 µm; 8 x 105 beads (27)) ± 100 nM TPA was added. Finally, cells were released and fixed at time points and assayed by flow cytometry (27).

Integrin Clustering and Internalization—1) Cells cultured on chambered coverslips in CO2-independent medium (Sigma) were stained with Alexa-555-conjugated 16B4 (labeling kit, Molecular Probes) and treated with 1 µM TPA, anti-mouse IgG (positive control), or left untreated (negative control). Four-dimensional (three-dimensional + time) data sets were obtained at 37 °C at 3-min intervals for a total time of 24 min. 2) Cells were starved overnight in medium containing 0.1% fetal bovine serum and treated either with 10 µM BIS or 1 µM TPA for 40 min at 37 °C, or cells were pretreated with 10 µM BIS for 15 min followed by addition of 1 µM TPA for 30 min. Control cells were untreated. Fixed cells (4% paraformaldehyde) were permeabilized (0.2% Triton X-100) and stained with mAb {alpha}2 integrin (2AE11, a kind gift from Dr. Fedor Berditchevski, University of Birmingham, Birmingham, UK) and anti-mouse Alexa-488-IgG. In each sample, 200 cells were analyzed. 3) Cells on coverslips were untreated (negative control), treated with 1 µM TPA for 15 min or 16B4 and anti-mouse Alexa-488-IgG (positive control). Fixed cells were permeabilized, stained with Alexa-555-conjugated 16B4, and embedded in Mowiol. Data were obtained by laser scanning confocal microscopy (LSM510, Carl Zeiss), and all images and volume and side view renderings were produced with BioImageXD software.

Structural Modeling—Structural models of human {alpha}2beta1 integrin headpiece domains were based on the crystal structures of the {alpha}Vbeta3 integrin (Ref. 2; Protein Data Bank ID: 1JV2 [PDB] ) and the {alpha}2 integrin-inserted domain (Ref. 12; Protein Data Bank ID: 1DZI [PDB] ). Structural coordinates were obtained from the RCSB Protein Data Bank (28) and sequence data from the Uni-Prot online data base (29). Sequences were aligned in Bodil v0.8 (30) and structures modeled using Modeler v7.7 (31). Molecular graphics were created using PyMOL v0.98 (32).

On-line Supplemental Material—Four-dimensional microscopy shows TPA-induced clustering and internalization of {alpha}2beta1 integrin in Saos-{alpha}2 cells. The movie (see supplemental material) was created using BioImageXD.


   RESULTS
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
DISCUSSION
 REFERENCES
 
TPA Induces a Ligand-independent but PKC{alpha}-dependent Aggregation and Internalization of {alpha}2beta1 Integrins—Virus and antibody-mediated {alpha}2beta1 clustering are known to activate PKC{alpha} (17). Here, the effect of the phorbol ester TPA, a PKC activator, on integrin clustering and internalization was investigated using Saos osteosarcoma cells transfected to express {alpha}2beta1 integrin (22). Cells were stimulated with TPA, and the experiments were done in the absence of collagen ligands. In four dimensional confocal microscopy studies, both fast macroclustering and internalization of {alpha}2beta1 integrin induced by TPA were observed (Fig. 1A and supplemental movie). The effect of TPA was comparable with, but not as extensive as, that obtained by secondary antibody-induced clustering, which was used as a positive control (Fig. 1A). As shown in Fig. 1B, the average time for the appearance of clear clusters after TPA addition was about 10 min, and the average time for their internalization was about 14 min. For secondary antibody-induced clustering, these times were about 3.5 and 7 min, respectively. No clustering or internalization was observed in negative control cells that were not stimulated in any way. Furthermore, BIS, a chemical inhibitor of PKCs, prevented the formation of TPA-induced integrin aggregates and their internalization (Fig. 1C). Thus, we propose bidirectional dialog between PKC{alpha} activation and integrin aggregation: receptor clustering activates PKC{alpha} (17) and PKC{alpha} further promotes the aggregation.

TPA Increases the Avidity of {alpha}2beta1-mediated Adhesion to Collagen in a PKC-dependent Manner—We have previously reported a fast and sensitive cell adhesion assay based on the use of collagen-coated polystyrene beads and flow cytometry (27). This sophisticated method allows accurate studies of the effect of TPA on the integrin avidity for collagen. CHO cells transfected to express either {alpha}2beta1, {alpha}10beta1, or mutant {alpha}2beta1 integrin ({alpha}2/{alpha}1 chimera) as their only collagen receptor (CHO-{alpha}2WT, CHO-{alpha}2/{alpha}1, CHO-{alpha}10WT; Refs. 20-22 and 33) were used.

The binding of CHO-{alpha}2WT cells to collagen I coated beads was detected by flow cytometry at successive time points (Fig. 2A). Cell adhesion to collagen I appeared to increase nearly linearly for up to 50 min before equilibrating. However, when CHO-{alpha}2WT cells were treated with TPA, a significantly faster adhesion, which reached its equilibrium in 40 min, was obvious. At every time point, TPA caused a 50% increase in cell adhesion compared with untreated CHO-{alpha}2WT cells (Fig. 2A). Increased adhesion was already clear at the 10 min time point, indicating the rapidity of TPA-induced activation (Fig. 2B).


Figure 1
View larger version (42K):
[in this window]
[in a new window]

  		FIGURE 1.
TPA induces ligand-independent clustering of {alpha}2beta1 integrins. A, Saos-{alpha}2 cells were treated with TPA, cluster-inducing antibodies (positive control), or left unstimulated (negative control) and imaged with four-dimensional live cell confocal microscopy. Three-dimensional volume renderings made with BioImageXD show that TPA induced internalization of {alpha}2beta1 integrin clusters. The white rectangle indicates a cell section rendered from the side and shown at top. See also the on-line supplemental movie. B, average time for the appearance and internalization of at least three clear integrin clusters was determined by visual inspection of optical slices and volume renderings. Clustering was not seen in untreated cells. C, Saos-{alpha}2 cells were treated with TPA or BIS ± TPA for 40 min, fixed, and imaged by confocal microscopy. Internalized {alpha}2beta1 integrin aggregates were determined from the images.

 
Previously, it has been shown that the cytoplasmic tail of the {alpha}2 subunit is required for outside-in signaling mediated by {alpha}2beta1 integrin (22, 33). In these studies, a chimeric {alpha}2 integrin subunit bearing an {alpha}1 cytoplasmic tail ({alpha}2/{alpha}1) appeared to be unable to mediate heterodimer-specific signals. To investigate the role of the {alpha}2 cytoplasmic tail in TPA-activated adhesion, CHO-{alpha}2/{alpha}1 cells were tested in time series. Temporal profiles of both untreated and TPA-treated CHO-{alpha}2/{alpha}1 cell adhesion to collagen I resembled the adhesion of CHO-{alpha}2WT cells. However, the TPA mediated increase in cell adhesion was substantially higher in CHO-{alpha}2/{alpha}1 cells than in CHO-{alpha}2WT cells (Fig. 2C). Thus, the swap mutation did not affect the ability of the receptor to become activated. CHO cells bearing {alpha}10beta1 integrin were analyzed similarly (CHO-{alpha}10WT; Fig. 2D). In this case, the adhesion in both TPA treated and untreated cells reached saturation at earlier time points than in CHO-{alpha}2WT cells (Fig. 2D). Furthermore at the 10-min time point, TPA treatment increased CHO-{alpha}10WT cell adhesion to collagen I more than seen in CHO-{alpha}2WT or CHO-{alpha}2/{alpha}1 cells indicating an earlier overall response. Altogether, the results show that the intracellular domains of integrin {alpha} subunits may not directly participate in regulation by TPA and that the effect is not limited to the {alpha}2beta1 heterodimer.

To verify that the observed increases in adhesion were mediated by {alpha}2beta1 integrin, a series of control experiments were performed using CHO-{alpha}2WT, CHO-{alpha}2/{alpha}1, and CHO-pAW cells. All cell types showed an invariably low level of interaction with negative control beads, which were either left uncoated or coated with BSA (Fig. 2E). Additionally, vector-transfected control cells, CHO-pAW cells, did not interact with collagen I-coated beads (Fig. 2E). However, CHO-{alpha}2WT and CHO-{alpha}2/{alpha}1 cells adhered strongly to collagen I-coated beads, revealing a specific interaction. This adhesion, both basal and TPA-mediated, was significantly decreased by pretreating cells with the {alpha}2 integrin-specific function blocking mAb P1H5, thereby verifying that adhesion occurred in all conditions via the {alpha}2beta1 integrin (Fig. 2E).

To confirm that the TPA-mediated increase in {alpha}2beta1 integrin avidity to collagen I uses a PKC-related signaling pathway, the PKC inhibitor, BIS, was tested in the presence and absence of TPA. When CHO-{alpha}2WT and CHO-{alpha}2/{alpha}1 cells were pretreated with BIS, the TPA-mediated cell adhesion to collagen decreased about 35%. However, BIS did not significantly alter the basal adhesion of CHO-{alpha}2WT cells to collagen I. In comparison, the PKC inhibitor slightly reduced basal adhesion in CHO-{alpha}2/{alpha}1 cells (Fig. 2F).

Integrin beta1 Subunit Is Essential for TPA-related Increase in {alpha}2-mediated Cell Adhesion to Collagen I—Talin is a cytoskeletal protein and a well know substrate for PKC (34). Talin binding to the cytosolic part of the integrin beta subunit is typically required for the initiation of integrin activation (35). To analyze the importance of the beta1 subunit in TPA-mediated integrin avidity regulation, we used GD25 cells expressing similar levels of either wild type {alpha}2beta1 or {alpha}2beta1 with Y783/795F mutations in the cytoplasmic tail of the beta1 subunit (25). Substituting these tyrosine residues in conserved NPXY motifs of the beta tail has previously shown to be sufficient to inhibit talin binding (35, 36). Here, in agreement with previous studies (25), both wild type {alpha}2beta1 and {alpha}2beta1mut integrin heterodimers could mediate cell attachment to collagen I-coated beads when analyzed by flow cytometry (Fig. 3). Additionally, TPA dramatically increased the collagen binding in GD25-{alpha}2beta1 cells as expected. In sharp contrast, TPA did not affect the activation of GD25-{alpha}2beta1mut cells (Fig. 3). The results suggest that integrin beta1 subunit is required for appropriate activation of {alpha}2beta1 heterodimer by TPA.


Figure 2
View larger version (22K):
[in this window]
[in a new window]

  		FIGURE 2.
TPA increases {alpha}2beta1-mediated adhesion to collagen. Cell adhesion via wild type {alpha}2 integrin (A; CHO-{alpha}2WT), a chimeric {alpha}2 subunit with an {alpha}1 cytoplasmic tail (C; CHO-{alpha}2/{alpha}1), or wild type {alpha}10 integrin (D; CHO-{alpha}10WT) to col I-coated beads with (bullet) or without ({circ}) 100 nM TPA is shown. B, TPA-induced adhesion of CHO-{alpha}2WT cells to collagen I is already clear at 10 min. E, CHO-{alpha}2WT-, CHO-{alpha}2/{alpha}1-, and vector-transfected control cells (CHO-pAW) had little interaction with uncoated or BSA-coated beads. Integrin-mediated adhesion to collagen I-coated beads is inhibited by P1H5 function blocking mAb to {alpha}2 integrin. F, pretreatment with BIS decreases TPA-mediated adhesion to collagen in CHO-{alpha}2WT and CHO-{alpha}2/{alpha}1. Data are mean ± S.D. for three triplicate experiments.

 
TPA Increases the Number of Conformationally Activated Integrins on the Cell Surface—Recent papers have identified monoclonal antibodies that recognize epitopes corresponding to specific activation states of the {alpha}2 integrin subunit (14, 37). Therefore, the possibility that treatment with TPA causes {alpha}2 integrin conformational activation in CHO-{alpha}2WT cells was tested. Cells were stimulated at different time points with TPA, and relative amounts of "total" and open {alpha}2 integrin subunit were determined by flow cytometry. Monoclonal {alpha}2 integrin-specific antibody 16B4, whose epitope is located outside the ligand binding region of the {alpha}2 subunit, was used for determination of total {alpha}2. Open {alpha}2 conformation was determined using mAb 12F1, which has recently been shown to favor an activated conformation of {alpha}2 subunit on platelets (14).

The expression of integrin {alpha}2 on the cell surface decreased in the presence of TPA between the first two measured time points (0 and 10 min) in all three independent experiments as shown in Fig. 4. This was not surprising given that some internalization of {alpha}2beta1 integrin was seen by confocal microscopy in TPA treated Saos cells (Fig. 1). Notwithstanding the initial decrease, the amount of {alpha}2 integrin on the cell surface remained stable after 10 min in all three experiments. In contrast, a significant increase in the number of 12F1 epitopes corresponding to the active conformation of {alpha}2 integrin was apparent in each experiment beginning at between 20 and 40 min after stimulation with TPA. The increase was transient in each case, lasting from 10 to 20 min before declining to near baseline levels (Fig. 4). Interestingly, the transient conformational activation of the {alpha}2 integrin seemed to occur later than the increase in avidity (within 10 min).

CHO-{alpha}2E336A Cells Retain Adhesion to Collagen, but the Mutation Inhibits TPA-related Conformational Change—In leukocyte beta2 integrins, e.g. in {alpha}Mbeta2 and {alpha}Lbeta2 integrins, ligand binding is shown first to cause a change in the conformation of the {alpha}I domain, including a downward movement of the {alpha}7 helix. This is followed by a similar change in the betaI domain, leading to separation of the leg domains of the {alpha} and beta subunits (1, 3, 4, 13, 38). A conserved glutamate residue on the {alpha}7 helix of the {alpha}I domain was suggested to act as an intrinsic ligand for the beta1I domain. The same structural link between the {alpha}I and betaI domains seems to be important in integrin inside-out signaling and regulation of affinity.


Figure 3
View larger version (16K):
[in this window]
[in a new window]

  		FIGURE 3.
beta1 subunit is required for TPA-related increase in {alpha}2beta1 adhesion to collagen I. GD25-{alpha}2beta1 cells and GD25-{alpha}2beta1mut cells, with beta1 subunit carrying Y783/795F mutations in its cytoplasmic tail, were incubated for 50 min with either col I- or BSA-coated beads ± 100 nM TPA. Cell binding to coated beads was assayed by flow cytometry (mean ± S.D., n = 3).

 
The corresponding glutamate in the {alpha}2I domain, the conserved Glu-336, may interact in a similar manner with the beta1I domain and participate in the switch between open and closed {alpha}2I domain conformations (Fig. 5A). We wanted, however, also to test the hypothesis that the conformational regulation of {alpha}2beta1 takes place in a different manner than the regulation of {alpha}Lbeta2 and {alpha}Mbeta2. Thus, we mutated amino acid residues Glu-336, Glu-309, and Tyr-410. Glu-309 is located close to the C terminus of the {alpha}7 or terminal helix of the {alpha}2I domain and potentially could interact with the beta1I domain metal binding sites (Fig. 5A). This residue was mutated to alanine to remove the negative charge of the side group. The mutation Y410A was constructed to probe the importance of the interaction between the {alpha}2 beta-propeller and the beta1I domain. A large surface area is buried between these two subunits, and there appears to be a specific interaction at the center of the {alpha}2 beta-propeller (Fig. 5A). From our molecular models of this specific interaction, based on the {alpha}Vbeta3 crystal structures (2), Tyr-410 could be one of the three aromatic residues involved in a cation-{pi} interaction with beta1K269. Disruption of this interaction might lead to defects in signaling and/or conformational activation.


Figure 4
View larger version (13K):
[in this window]
[in a new window]

  		FIGURE 4.
TPA increases conformationally activated integrins on cell surface. In three independent experiments, TPA-induced (100 nM) conformational activation over time of CHO-{alpha}2WT cells was determined using mAbs recognizing either total ({circ}; 16B4) or active, open (bullet; 12F1) {alpha}2 integrin.

 
CHO cells transfected to express integrin {alpha}2 subunits carrying either E309A, Y410A, or E336A mutations (CHO-{alpha}2E309A, CHO-{alpha}2Y410A, and CHO-{alpha}2E336A) were tested by flow cytometry for their ability to adhere to collagen I-coated polystyrene beads. It appeared that the base level adhesion of CHO-{alpha}2E336A to collagen I was clearly affected compared with CHO-{alpha}2WT cells (Fig. 5B). Mutation Y410A also decreased {alpha}2 integrin binding to collagen I, whereas mutation E309A had no effect (Fig. 5B). Reduced CHO-{alpha}2E336A cell binding to collagen I is in agreement with previous studies indicating that {alpha}L and {alpha}M integrins lose their ability to bind their ligands after the mutation of the residue corresponding to E336 in {alpha}2 (E310A in {alpha}L and E320A in {alpha}M; Refs. 3 and 39). Notably, CHO-{alpha}2E336A cells retained a low level of avidity to collagen and were able to spread on collagen I-coated surfaces in 2 h (Fig. 5C). However, CHO-{alpha}2WT cells, as well as CHO-{alpha}2Y410A and CHO-{alpha}2E309A cells, spread significantly more quickly on collagen (Fig. 5C).


Figure 5
View larger version (34K):
[in this window]
[in a new window]

  		FIGURE 5.
Mutation E336A inhibits the TPA-related increase in 12F1 positive integrins. A, a ribbon diagram of the human {alpha}2beta1 integrin head region in an open conformation based on crystal structures of the {alpha}Vbeta3 integrin and the {alpha}2I domain. Integrin {alpha}2I domain is blue, beta-propeller is pink, beta1I domain is gray, and metal ions are yellow spheres. Positions Glu-309, Glu-336, and Tyr-410 are indicated. B, CHO cells expressing either wild type (CHO-{alpha}2WT) or mutated (CHO-{alpha}2Y410A, CHO-{alpha}2E309A, or CHO-{alpha}2E336A) {alpha}2 integrin were incubated with collagen I-coated beads or BSA-coated negative control beads for 50 min. C, integrin-mediated cell spreading on type I collagen was analyzed after 2 h in serum-free Dulbecco's modified Eagle's medium + 50 µM cycloheximide. Negative control wells were coated with BSA. Cells in 16 representative fields were analyzed for total cells attached and percentage of cells spread. A spread cell is one with a clear ring of cytoplasm around the nucleus. D, TPA-induced (100 nM) conformational activation over time of {alpha}2E336A integrin was studied using mAbs recognizing either total ({circ}; 16B4) or active open (bullet; 12F1) {alpha}2 integrin.

 
The TPA-induced conformational activation of the {alpha}2 integrin with the E336A mutation was studied in a flow cytometry based assay by using CHO-{alpha}2E336A cells and antibodies recognizing either total or open {alpha}2 integrins on the cell surface. In CHO-{alpha}2E336A cells, the level of total {alpha}2 expression was stable over the course of the experiment (Fig. 5D). Interestingly, in these cells, as opposed to cells bearing the wild type {alpha}2 subunit (Fig. 2A), the TPA treatment did not induce an increase in the amount of the active {alpha}2 integrin conformation recognized by mAb 12F1 (Fig. 5D).

Mutation {alpha}2E336A Prevents neither the TPA-related Increase in Avidity for Collagen nor {alpha}2beta1 Aggregation—When CHO-{alpha}2 cells with E336A, E309A, or Y410A mutations were treated with TPA, their avidity to collagen I-coated polystyrene beads increased remarkably (Fig. 6A). Thus, {alpha}2beta1 integrin avidity is also regulated by an E336-independent mechanism unrelated to the changes in integrin conformation. The TPA-induced cluster formation of {alpha}2beta1 integrin was also studied in CHO-{alpha}2WT and CHO-{alpha}2E336A cells using three-dimensional microscopy. TPA induced the formation of macroclusters on CHO-{alpha}2 cells (Fig. 6B), which is in full agreement with our experiments using Saos-{alpha}2 cells (Fig. 1). Receptor clustering was evident in both CHO-{alpha}2WT and CHO-{alpha}2E336A cells (Fig. 6B). The clustering was more difficult to detect in CHO cells than in Saos cells because of the dot-like appearance of the integrin stain. However, clustering is clearly visible in optical sections from the tops of the cells in which it looks similar to clusters induced by antibody cross-linking, while it is absent in negative control cells (Fig. 6B). These results indicate that, in addition to conformational regulation, TPA also induces other mechanisms regulating integrin activity. We propose that ligand-independent {alpha}2beta1 integrin clustering is one of the mechanisms, which increases avidity.


   DISCUSSION
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
REFERENCES
 
The interaction of {alpha}2beta1 integrin and collagenous matrix has been implicated in a number of biological and pathological processes such as thrombosis, inflammation, angiogenesis, and wound healing. The precise regulation of integrin {alpha}2beta1 activation is very important for example for platelet function (40). In general, integrin activation is an essential mechanism for the formation of matrix adhesion sites. Thus, understanding the mechanism of {alpha}2beta1 activation thoroughly will provide insight into a cellular event of broad biological significance. Here, we report that {alpha}2beta1 integrin activation is regulated by two synergistic mechanisms: receptor clustering and conformational activation.

The structural basis of outside-in signaling in leukocyte beta2 integrins has been investigated in depth (1, 38). The integrins are considered to have at least three different conformations with distinct abilities to bind their ligands. In inactive integrins, the ligand binding head part is bent toward the plasma membrane in a manner that makes the binding of large ligands difficult. However, inside-out signaling mechanisms such as talin binding to the cytoplasmic domains of the beta subunits (35) can induce a switchblade-like movement in the integrin raising the integrin head part up. The avidity of standing integrin for its ligand can still be increased by further conformational modifications. In {alpha}I domain integrins the high avidity conformation has been recognized as the open conformation of the {alpha}I domain. Here, we have studied a model in which {alpha}2beta1 integrins were activated by TPA. It was clear that the TPA effect on integrin avidity could, at least partially, be explained by the ability of TPA to switch {alpha}2I domains from the closed to the open conformation. This conformational change was studied using 12F1 anti-{alpha}2 mAb binding to the cell surface. In a recent study, the monoclonal antibody 12F1 was shown to favor the activated, open conformation of the {alpha}2 subunit on platelets (14). Monoclonal antibody 16B4, which recognizes an epitope located outside the ligand binding region of the {alpha}2 subunit, was used to determinate the total {alpha}2 on the cell surface. Previous studies on {alpha}Lbeta2 and {alpha}Mbeta2 integrins have proposed that a glutamate residue in the {alpha}7 helix of the {alpha}I domain (E320 in {alpha}L and E310 in {alpha}M) can act as an intrinsic ligand for the beta subunit and mediate conformational regulation between the {alpha}I domain and the beta subunit in two directions (3, 4). Our molecular model of {alpha}2beta1 integrin supports the idea that Glu-336 in the {alpha}2 subunit could have a similar role. This hypothesis was tested using CHO cells transfected with the {alpha}2 subunit harboring the E336A mutation. E336A prevented TPA-dependent increases in the number of 12F1 epitopes on the cell surface indicating the essential role of Glu-336 in conformational regulation.


Figure 6
View larger version (40K):
[in this window]
[in a new window]

  		FIGURE 6.
Mutation {alpha}2E336A prevents neither the TPA-related increase in avidity for collagen nor {alpha}2beta1 aggregation. A, cells were incubated for 50 min with either collagen I- or BSA-coated beads ± 100 nM TPA and assayed by flow cytometry (mean ± S.D., n = 3). B, cells were treated for 15 min with either TPA or secondary antibodies (positive control), fixed, and imaged by confocal microscopy. Optical sections from the tops of the cells (left) and differential interference contrast images (right) are shown. No clustering was observed in untreated cells. Dotted lines indicate that cells were in separate visual fields.

 
Despite the fact that integrin conformation was shown to participate in the regulation of avidity, it seemed clear that additional mechanisms are likely to exist. This conclusion was based on two observations: first, the conformational change in {alpha}2beta1 integrins was observed only after 10 min, while the avidity started to increase earlier. Typically, a transient increase in the number of 12F1 epitopes occurred 20-40 min after stimulation with TPA. Second, E336A mutation could not block the effect of TPA. In contrast, the E310A mutation in {alpha}L, which is an equivalent to E336A in {alpha}2, prevents the effect of TPA on avidity (8). In our experiments, base-line cell adhesion was lower in CHO-{alpha}2E336A than in CHO-{alpha}2WT cells, which is in agreement with previous papers that have described the loss of ligand binding by {alpha}L and {alpha}M integrins after mutation in the corresponding residue (3).

The clustering of {alpha}Lbeta2 is seen after ligand binding, and it is an important mechanism in the strengthening of adhesion (8). Ligand binding to {alpha}2beta1 integrin is known to induce clustering and concomitant activation of specific signaling pathways (17). Thus, ligand-dependent receptor clustering is a well known phenomenon. However, the role of ligand-independent integrin clustering in the regulation of avidity has been a controversial issue (41, 42). Here, using confocal microscopy, TPA was documented to induce the macroclustering of {alpha}2beta1 integrins in {alpha}2beta1 overexpressing Saos-{alpha}2beta1 osteosarcoma cells and CHO-{alpha}2beta1 cells. The role of integrin aggregation was supported by two facts: clustering took place very quickly, in less than 10 min after TPA treatment similarly to the increase in avidity. Additionally, the E336A mutation could not prevent integrin clustering, and it could not prevent the increase in avidity.

The effects of TPA on {alpha}2beta1 avidity and clustering are likely mediated by activation of PKC, since a chemical inhibitor, bisindolylmaleimide, could block the effect of TPA. Interestingly, we have previously shown that {alpha}2beta1 clustering can activate the {alpha} isoform of PKC, and specific inhibitors of PKC{alpha} prevent clustering-dependent integrin internalization (17). Thus, our results propose that {alpha}2beta1 integrin clustering and PKC may regulate each other in both directions. Here, the structural requirements of TPA-mediated {alpha}2beta1 integrin activations were also studied. Our earlier studies have shown that an integrin chimera having the {alpha}2 extracellular domain, and the cytoplasmic domain of {alpha}1 the subunit ({alpha}2/{alpha}1) cannot mediate heterodimer-specific outside-in signals (22). In this study, however, this swap mutation neither destroyed the ability of the receptor to become activated by TPA nor affected the time course of activation. In both {alpha}2- and mutant {alpha}2/{alpha}1-mediated collagen I binding, the TPA-dependent increase was already clear at the 10-min time point. These results suggest that the intracellular domains of integrin {alpha} subunits may not directly participate in regulation by TPA. In fact, collagen binding activity by CHO cells transfected to express {alpha}10beta1 integrin was also activated by TPA. One previous study suggests that PKC might interact directly with beta1 subunit (43) or through talin-containing integrin activation complex (44). For example {alpha}IIbbeta3 integrin has previously shown to be activated by TPA only when PKC{alpha} and talin are present (44). In agreement, cells expressing wild type {alpha}2 and talin-binding defective beta1 subunit (GD25-{alpha}2beta1mut) were not stimulated by TPA. The results suggest that instead of the {alpha} subunit, the beta subunit is required for TPA-mediated activation.

We conclude that {alpha}2beta1 integrin forms clusters upon TPA induced activation and that receptor aggregates may contribute to the increase in the avidity of adhesion. Similarly, a recent paper has suggested that ligand free clusters of {alpha}Lbeta2 integrin may occur (45), while in other experimental models, receptor clustering has only followed ligand binding (8, 9). In addition, some earlier studies have suggested that clustering would regulate integrin avidity even without conformational activation of individual receptors (46, 47). This report and our previous results suggest that the same signaling proteins that are activated by ligand mediated clustering may also initiate ligand-free clustering. Furthermore, structural activation seems to be required for the high avidity configuration of the {alpha}2beta1 integrin. Thus, we propose a model in which {alpha}2beta1 clustering and conformational activation take place in a synergistic manner.


   FOOTNOTES
 
* This work was funded by the Academy of Finland, the Technology Development Center of Finland, the Sigrid Jusélius Foundation, the Finnish Cancer Association, the Center of Excellence Program of Åbo Akademi, and the National Graduate School of Informational and Structural Biology. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. Back

Formula The on-line version of this article (available at http://www.jbc.org) contains a supplemental movie. Back

1 To whom correspondence should be addressed. Tel.: 358-2-333-6879; Fax: 358-2-333-6860; E-mail: jyrki.heino{at}utu.fi.

2 The abbreviations used are: TPA, 12-O-tetradecanoylphorbol-13-acetate; CHO, Chinese hamster ovary; col I, collagen I; BSA, bovine serum albumin; mAb, monoclonal antibody; BIS, bisindolylmaleimide. Back


   ACKNOWLEDGMENTS
 
We are grateful to Professor Kristofer Rubin from Uppsala University, Sweden, and Professor Deane F. Mosher from University of Wisconsin for providing us GD25 cells. We thank Maria Tuominen, Jouko Sandholm, Kalle Pahajoki, and Elina Dadu for excellent technical assistance.



   REFERENCES
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Springer, T. A., and Wang, J. H. (2004) Adv. Protein Chem. 68, 29-63[Medline] [Order article via Infotrieve]
  2. Xiong, J. P., Stehle, T., Diefenbach, B., Zhang, R., Dunker, R., Scott, D. L., Joachimiak, A., Goodman, S. L., and Arnaout, M. A. (2001) Science 294, 339-345[Abstract/Free Full Text]
  3. Alonso, J. L., Essafi, M., Xiong, J. P., Stehle, T., and Arnaout, M. A. (2002) Curr. Biol. (Lond.) 12, 340-342[CrossRef]
  4. Yang, W., Shimaoka, M., Salas, A., Takagi, J., and Springer, T. A. (2004) Proc. Natl. Acad. Sci. U. S. A. 101, 2906-2911[Abstract/Free Full Text]
  5. Jin, M., Andricioaei, I., and Springer, T. A. (2004) Structure (Lond.) 12, 2137-2147[Medline] [Order article via Infotrieve]
  6. Salas, A., Shimaoka, M., Kogan, A. N., Harwood, C., von Andrian, U. H., and Springer, T. A. (2004) Immunity 20, 393-406[CrossRef][Medline] [Order article via Infotrieve]
  7. Sarantos, M. R., Raychaudhuri, S., Lum, A. F., Staunton. D. E., and Simon, S. I. (2005) J. Biol. Chem. 280, 28290-28298[Abstract/Free Full Text]
  8. Kim, M., Carman, C. V., Yang, W., Salas, A., and Springer, T. A. (2004) J. Cell Biol. 167, 1241-1253[Abstract/Free Full Text]
  9. Cluzel, C., Saltel, F., Lussi, J., Paulhe, F., Imhof, B. A., and Wehrle-Haller, B. (2005) J. Cell Biol. 171, 383-392[Abstract/Free Full Text]
  10. Loftus, J. C., and Albrecht, R. M. (1984) J. Cell Biol. 99, 822-829[Abstract/Free Full Text]
  11. White, D. J., Puranen, S., Johnson, M. S., and Heino, J. (2004) Int. J. Biochem. Cell Biol. 36, 1405-1410[CrossRef][Medline] [Order article via Infotrieve]
  12. Emsley, J., Knight, C. G., Farndale, R. W., Barnes, M. J., and Liddington, R. C. (2000) Cell 101, 47-56[CrossRef][Medline] [Order article via Infotrieve]
  13. Shimaoka, M., Xiao, T., Liu, J.-H., Yang, Y., Dong, Y., Jun, C.-D., McCormack, A., Zhang, R., Joachimiak, A., Takagi, J., Wang, J.-H., and Springer, T. A. (2003) Cell 112, 99-111[CrossRef][Medline] [Order article via Infotrieve]
  14. Cruz, M. A., Chen, J., Whitelock, J. L., Morales, L. D., and Lopez, J. A. (2005) Blood 105, 1986-1991[Abstract/Free Full Text]
  15. Velling, T., Risteli, J., Wennerberg, K., Mosher, D. F., and Johansson, S. (2002) J. Biol. Chem. 277, 37377-37381[Abstract/Free Full Text]
  16. Li, S., Van Den Diepstraten, C., D'Souza, S. J., Chan, B. M., and Pickering, J. G. (2003) Am. J. Pathol. 163, 1045-1056[Abstract/Free Full Text]
  17. Upla, P., Marjomäki, V., Kankaanpää, P., Ivaska, J., Hyypiä, T., Van Der Goot, F. G., and Heino, J. (2004) Mol. Biol. Cell 15, 625-636[Abstract/Free Full Text]
  18. Polanowska-Grabowska, R., and Gear, A. R. (1999) Arterioscler. Thromb. Vasc. Biol. 19, 3044-3054[Abstract/Free Full Text]
  19. Riikonen, T., Westermarck, J., Koivisto, L., Broberg, A., Kähäri, V.-M., and Heino, J. (1995) J. Biol. Chem. 270, 13548-13552[Abstract/Free Full Text]
  20. Nykvist, P., Tu, H., Ivaska, J., Käpylä, J., Pihlajaniemi, T., and Heino, J. (2000) J. Biol. Chem. 275, 8255-8261[Abstract/Free Full Text]
  21. Käpylä, J., Jäälinoja, J., Tulla, M., Ylöstalo, J., Nissinen, L., Viitasalo, T., Vehviläinen, P., Marjomäki, V., Nykvist, P., Säämänen, A.-M., Farndale, R. W., Birk, D. E., Ala-Kokko, L., and Heino, J. (2004) J. Biol. Chem. 279, 51677-51687[Abstract/Free Full Text]
  22. Ivaska, J., Reunanen, H., Westermarck, J., Koivisto, L., Kähäri, V.-M., and Heino, J. (1999) J. Cell Biol. 147, 401-416[Abstract/Free Full Text]
  23. Wennerberg, K., Lohikangas, L., Gullberg, D., Pfaff, M., Johansson, S., and Fässler, R. (1996) J. Cell Biol. 132, 227-238[Abstract/Free Full Text]
  24. Wennerberg, K., Armulik, A., Sakai, T., Karlsson, M., Fässler, R., Schaefer, E. M., Mosher, D. F., and Johansson, S. (2000) Mol. Cell. Biol. 20, 5758-5765[Abstract/Free Full Text]
  25. Grundström, G., Mosher, D. F., Sakai, T., and Rubin, K. (2003) Exp. Cell Res. 291, 463-473[CrossRef][Medline] [Order article via Infotrieve]
  26. Jokinen, J., Dadu, E., Nykvist, P., Käpylä, J., White, D. J., Ivaska, J., Vehviläinen, P., Reunanen, H., Larjava, H., Häkkinen, L., and Heino, J. (2004) J. Biol. Chem. 279, 31956-31963[Abstract/Free Full Text]
  27. Connors, W. L., and Heino, J. (2005) Anal. Biochem. 337, 246-255[CrossRef][Medline] [Order article via Infotrieve]
  28. Berman, H. M., Westbrook, J., Feng, Z., Gilliland, G., Bhat, T. N., Weissig, H., Shindyalov, I. N., and Bourne, P. E. (2000) Nucleic Acids Res. 28, 235-242[Abstract/Free Full Text]
  29. Bairoch, A., Apweiler, R., Wu, C. H., Barker, W. C., Boeckmann, B., Ferro, S., Gasteiger, E., Huang, H., Lopez, R., Magrane, M., Martin, M. J., Natale, D. A., O'Donovan, C., Redaschi, N., and Yeh, L. S. (2005) Nucleic Acids Res. 33, D154-D159[Abstract/Free Full Text]
  30. Lehtonen, J. V., Rantanen, V.-V., Still, D.-J., Ekholm, J., Björklund, D., Iftikhar, Z., Huhtala, M., Jussila, A., Jaakkola, J., Pentikäinen, O., Nyrönen, T., Salminen, T. A., Gyllenberg, M., and Johnson, M. S. (2004) J. Comput. Aided Mol. Des. 18, 401-419[CrossRef][Medline] [Order article via Infotrieve]
  31. Marti-Renom, M. A., Stuart, A., Fiser, A., Sánchez, R., Melo, F., and Sali, A. (2000) Annu. Rev. Biophys. Biomol. Struct. 29, 291-325[CrossRef][Medline] [Order article via Infotrieve]
  32. DeLano, W. L. (2002) The PyMOL Molecular Graphics System, DeLano Scientific, San Carlos, CA
  33. Ivaska, J., Nissinen, L., Immonen, N., Eriksson, J. E., Kähäri, V.-M., and Heino, J. (2002) Mol. Cell. Biol. 22, 1352-1359[Abstract/Free Full Text]
  34. Litchfield, D. W., and Ball, E. H. (1986) Biochem. Biophys. Res. Commun. 134, 1276-1283[CrossRef][Medline] [Order article via Infotrieve]
  35. Tadokoro, S., Shattil, S. J., Eto, K., Tai, V., Liddington, R. C., de Pereda, J. M., Ginsberg, M. H., and Calderwood, D. A. (2003) Science 302, 103-106[Abstract/Free Full Text]
  36. Czuchra, A., Meyer, H., Legate, K. R., Brakebusch, C., and Fässler, R. (2006) J. Cell Biol. 174, 889-899[Abstract/Free Full Text]
  37. Van de Walle, G. R., Vanhoorelbeke, K., Majer, Z., Illyes, E., Baert, J., Pareyn, I., and Deckmyn, H. (2005) J. Biol. Chem. 280, 36873-36882[Abstract/Free Full Text]
  38. Arnaout, M. A., Mahalingam, B., and Xiong, J. P. (2005) Annu. Rev. Cell Dev. Biol. 21, 381-410[CrossRef][Medline] [Order article via Infotrieve]
  39. Huth, J. R., Olejniczak, E. T., Mendoza, R., Liang, H., Harris, E. A., Lupher, M. L., Wilson, A. E., Jr., Fesik, S. W., and Staunton, D. E. (2000) Proc. Natl. Acad. Sci. U. S. A. 97, 5231-5236[Abstract/Free Full Text]
  40. Santoro, S. A., and Zutter, M. M. (1995) Thromb. Haemostasis 74, 813-821[Medline] [Order article via Infotrieve]
  41. Bazzoni, G., and Hemler, M. (1998) Trends Biochem. Sci. 23, 30-34[CrossRef][Medline] [Order article via Infotrieve]
  42. Carman, C. V., and Springer, T. A. (2003) Curr. Opin. Cell Biol. 15, 547-556[CrossRef][Medline] [Order article via Infotrieve]
  43. Ng, T., Shima, D., Squire, A., Bastiaens, P. I., Gschmeissner, S., Humphries, M. J., and Parker, P. J. (1999) EMBO J. 18, 3909-3923[CrossRef][Medline] [Order article via Infotrieve]
  44. Han, J., Lim, C. J., Watanabe, N., Soriani, A., Ratnikov, B., Calderwood, D. A., Puzon-McLaughlin, W., Lafuente, E. M., Boussiotis, V. A., Shattil, S. J., and Ginsberg, M. H. (2006) Curr. Biol. 16, 1796-1806[CrossRef][Medline] [Order article via Infotrieve]
  45. Cambi, A., Joosten, B., Koopman, M., de Lange, F., Beeren, I., Torensma, R., Fransen, J. A., Garcia-Parajo, M., van Leeuwen, F. N., and Figdor, C. G. (2006) Mol. Biol. Cell 17, 4270-4281[Abstract/Free Full Text]
  46. Van Kooyk, Y., and Figdor, C. G. (2000) Curr. Opin. Cell Biol. 12, 542-547[CrossRef][Medline] [Order article via Infotrieve]
  47. Hogg, N., Henderson, R., Leitinger, B., McDowall, A., Porter, J., and Stanley, P. (2002) Immunol. Rev. 186, 164-171[CrossRef][Medline] [Order article via Infotrieve]

Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 Proc. Natl. Acad. Sci. USAHome page
M. W. Miller, S. Basra, D. W. Kulp, P. C. Billings, S. Choi, M. P. Beavers, O. J. T. McCarty, Z. Zou, M. L. Kahn, J. S. Bennett, et al.
Small-molecule inhibitors of integrin {alpha}2{beta}1 that prevent pathological thrombus formation via an allosteric mechanism
PNAS, January 20, 2009; 106(3): 719 - 724.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Supplemental Data
Right arrow All Versions of this Article:
282/19/14675    most recent
M700759200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Connors, W. L.
Right arrow Articles by Heino, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Connors, W. L.
Right arrow Articles by Heino, J.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2007 by the American Society for Biochemistry and Molecular Biology.
Advertisement
spacer
Advertisement
Advertisement